Flupentixol/melitracen for chronic refractory cough after treatment failure with other neuromodulators

2021 ◽  
Vol 25 (8) ◽  
pp. 648-654
Author(s):  
Q. Chen ◽  
M. Zhang ◽  
F. Si ◽  
S. Wang ◽  
X. Xu ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Adverse Effects ◽  
Rating Scale ◽  
Anxiety And Depression ◽  
Generalized Anxiety ◽  
Treatment Cessation ◽  
Health Questionnaire ◽  
Leicester Cough Questionnaire ◽  
Patient Health ◽  
Hamilton Anxiety Rating Scale

BACKGROUND: Gabapentin and baclofen are recommended for the treatment of chronic refractory cough (CRC). We investigated the efficacy of flupentixol/melitracen in patients unresponsive to these neuromodulators.METHODS: A total of 101 patients with CRC who failed to respond to gabapentin and baclofen were recruited, and treated with flupentixol/melitracen. The prevalence of cough resolution and changes in the Cough Symptom Score (CSS), cough thresholds to capsaicin, Hull Airway Reflux Questionnaire (HARQ), Leicester Cough Questionnaire (LCQ), Generalized Anxiety Disorder-7, Hamilton Anxiety Rating Scale, Patient Health Questionnaire-9, and Hamilton Depression Rating Scale-24 were evaluated after treatment.RESULTS: Ninety-eight patients (97.0%) completed the study. The overall successful cough resolution rate was 62.4% (63/101). Cough resolution was accompanied by an obvious decrease in the CSS and HARQ score and a remarkable increase in cough thresholds to capsaicin challenge and LCQ score, whereas anxiety and depression scores did not change significantly. The prevalence of adverse effects (e.g., insomnia and dizziness) was 21.8%. The prevalence of cough recurrence within 2 weeks after treatment cessation was 17.8%.CONCLUSION: Flupentixol/melitracen may be an efficacious option for CRC unresponsive to other neuromodulators.

scholarly journals The role of sex and gender in the changing levels of anxiety and depression during the COVID-19 pandemic: A cross-sectional study

2021 ◽  
Vol 17 ◽  
pp. 174550652110629
Author(s):  
Hoda Seens ◽  
Shirin Modarresi ◽  
James Fraser ◽  
Joy C MacDermid ◽  
David M Walton ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Anxiety And Depression ◽  
Generalized Anxiety ◽  
Sex And Gender ◽  
Health Questionnaire ◽  
Cross Sectional ◽  
Maximum Score ◽  
Patient Health ◽  
And Gender

Background: Several studies have assessed the impact of the COVID-19 pandemic on anxiety and depression, but have not focused on the role of sex and gender. This study compared changes in the levels of anxiety and depression (pre- and post-COVID) experienced by individuals of various sexes and genders. Methods: We used a cross-sectional online survey that assessed pre- and post-COVID symptoms of anxiety (Generalized Anxiety Disorder-2) and depression (Patient Health Questionnaire-9). General linear modeling (fixed model factorial analysis of variance) was used to evaluate changes in anxiety and depression between pre- and post-pandemic periods and explore differential effects of sex and gender on those changes. Results: Our study included 1847 participants from 43 countries and demonstrated a percentage increase of 57.1% and 74.2% in anxiety and depression, respectively. For the Generalized Anxiety Disorder-2 scale (maximum score 6), there was a mean increase in anxiety by sex for male, female, and other of 1.0, 1.2, and 1.4, respectively; and by gender for man, woman, and others of 0.9, 1.3, and 1.6, respectively. For the Patient Health Questionnaire-9 (maximum score 27), there was a mean increase in depressive symptoms by sex for male, female, and other of 3.6, 4.7, and 5.5 respectively; and by gender for man, woman, and others of 3.3, 4.8, and 6.5, respectively. Conclusion: During COVID-19, there was an increase in anxiety and depressive symptoms for all sexes and genders, with the greatest increases reported by those identifying as non-male and non-men.

scholarly journals USO PROBLEMÁTICO Y ADICTIVO DE INTERNET Y RIESGO DE ANSIEDAD Y DEPRESIÓN EN ADOLESCENTES

2021 ◽  
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Internet Use ◽  
Patient Health Questionnaire ◽  
Generalized Anxiety ◽  
Health Questionnaire ◽  
Redes Sociales ◽  
Patient Health ◽  
On Line

El presente trabajo estudia la comorbilidad entre los usos problemático y adictivo de internet y los trastornos de ansiedad y depresión explorando la posible relación entre ambos fenómenos y las variables influyentes en la mayor o menor intensidad de dicha relación En el contexto de un programa de Cribado e Intervención Breve Digital dirigido a la prevención del uso problemático de internet (PiensaTIC) un total de 1.239 alumnos de enseñanzas secundarias ( 54% mujeres y 46% varones) de diez centros educativos de la provincia de Málaga cumplimentaron de forma on-line las escalas CIUS (Compulsive Internet Use Scale) para evaluar el uso problemático genérico de internet y el cuestionario YDQ (Young's Diagnostic Questionnaire) para evaluar el uso adictivo especifico de internet referido al uso de redes sociales y videojuegos. Asimismo contestaron las escalas GAD-2 (Generalized Anxiety Disorder-2) y PHQ-2 (Patient Health Questionnaire-2) diseñadas para realizar un cribado del riesgo de trastorno de ansiedad generalizada y de depresión. El uso compulsivo genérico de internet se asoció significativamente a un mayor riesgo de ansiedad y depresión siendo esta relación más evidente entre las alumnas que entre los alumnos. El uso intensivo de redes sociales (20 h semanales o más) está asociado a un mayor riesgo de ansiedad y depresión especialmente si cumple los criterios marcados por el YDQ como uso adictivo, no encontrándose diferencias de género en esta relación. No se encontró relación entre el uso adictivo de video juegos y el riesgo de ansiedad o depresión. Estos resultados sugieren la necesidad de evaluar de forma más exhaustiva la relación entre distintos trastornos psicopatológicos y los usos compulsivos y adictivos de internet como trastornos comórbidos que puedan cumplir los criterios de un trastorno de patología dual.

Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial

2011 ◽  
Vol 26 (4) ◽  
pp. 461-470 ◽  
Author(s):  
Sallie J Hadley ◽  
Francine S Mandel ◽  
Edward Schweizer
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Rating Scale ◽  
Controlled Trial ◽  
Generalized Anxiety ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference ◽  
Hamilton Anxiety Rating Scale

To evaluate the efficacy of pregabalin in facilitating taper off chronic benzodiazepines, outpatients ( N = 106) with a lifetime diagnosis of generalized anxiety disorder (current diagnosis could be subthreshold) who had been treated with a benzodiazepine for 8–52 weeks were stabilized for 2–4 weeks on alprazolam in the range of 1–4 mg/day. Patients were then randomized to 12 weeks of double-blind treatment with either pregabalin 300–600 mg/day or placebo while undergoing a gradual benzodiazepine taper at a rate of 25% per week, followed by a 6-week benzodiazepine-free phase during which they continued double-blind study treatment. Outcome measures included ability to remain benzodiazepine-free (primary) as well as changes in Hamilton Anxiety Rating Scale (HAM)-A and Physician Withdrawal Checklist (PWC). At endpoint, a non-significant higher proportion of patients remained benzodiazepine-free receiving pregabalin compared with placebo (51.4% vs 37.0%). Treatment with pregabalin was associated with significantly greater endpoint reduction in the HAM-A total score versus placebo (−2.5 vs +1.3; p < 0.001), and lower endpoint mean PWC scores (6.5 vs 10.3; p = 0.012). Thirty patients (53%) in the pregabalin group and 19 patients (37%) in the placebo group completed the study, reducing the power to detect a significant difference on the primary outcome. The results on the anxiety and withdrawal severity measures suggest that switching to pregabalin may be a safe and effective method for discontinuing long-term benzodiazepine therapy.

scholarly journals The Roles of S100B , IL-1β and IL-2 as Neuroinflammation Biomarkers in Generalized Anxiety Disorder

2021 ◽  
Author(s):  
Zhongxia Shen ◽  
Lijun Cui ◽  
Lie Ren ◽  
Mincai Qian ◽  
Yonggui Yuan ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Rating Scale ◽  
Generalized Anxiety ◽  
Serum S100b ◽  
Significant Difference ◽  
Hamilton Anxiety Rating Scale ◽  
Neuro Inflammation ◽  
Roc Area ◽  
Inflammatory Molecules

Abstract Introduction: S100B is a neurotrophic factor regulates neuronal growth and plasticity via activating astrocytes and microglia through production of neuro-inflammatory molecules like interleukin (IL)-1β involved in many mental disorders, few studies have combined S100B and cytokines to explore their roles as neuro-inflammatory biomarkers in Generalized Anxiety Disorder (GAD). Methods: Serum S100B and cytokines (IL-1β , IL-2, IL-4 and IL-10) of 108 untreated GAD cases and 123 healthy controls were determined by enzyme linked-immuno-sorbent assay (ELISA) and then compared, while Hamilton Anxiety Rating Scale (HAMA) scores were measured to evaluate anxiety severity. Results: The serum S100B and IL-1β, IL-2 levels of GAD cases were lower than HC significantly (P<0.001), the IL-4 level of GAD were higher than HC (P<0.001), while IL-10 had no significant difference between two groups (P=0.215). The ROC area of S100B, IL-1β, IL-2 and IL-4 in diagnosis of GAD was (0.740 ± 0.032) , (0.900 ± 0.021) , (0.920 ± 0.018) and (0.696 ± 0.037) , all of them suggested a good predicting value (P < 0.001) , while the ROC area of IL-10 was (0.544 ± 0.038) (P = 0.251). The sensitivity of S-100B, IL-1β, IL-2 in diagnosis of GAD was 73.1%, 80.6%, 85.2%, while the specificity was 61.0%, 86.2%, 80.5%. The combination ROC area of S100B, IL-1β , IL-2 and IL-4 was (0.985 ± 0.006)(P < 0.001). Serum S100B was positively correlated with IL-2 and IL-4 (P <0.05)., while was negatively with HAMA scores (P <0.001). Conclusion: The serum S-100B, IL-1β, IL-2 levels of GAD were down-regulated while IL-4 was up-regulated, both IL-2 and IL-4 had a good diagnosis value in GAD separately while the combination of S100B and cytokines had a better diagnosis value which means the neuro-inflammation in GAD is a network regulated by many factors.

Sign in / Sign up

Export Citation Format

Share Document